亞洲益菌中心 (Asia Microbiota Bank)目前正在開展一項關於使用人類益生菌移植治療 (Human Microbiota Transplant, HMT) 來緩解自閉症(Autism Spectrum Disorder, ASD) 患者的消化系統症狀的臨床研究計劃。此項臨床研與一家香港私人醫療診所合作，我們中心負責提供口服HMT的治療方法來舒緩ASD患者腸胃症狀。如欲參與此計劃，或了解更多有關此計劃之詳情，歡迎透過電子郵件 health@asiabiobank.com 或致電+852 5190 6282與我們聯絡。
Background
The prevalence of children with autistic spectrum disorders (ASD) is increasing worldwide. The cause of ASD is poorly understood and involves interplay of different genetic and environmental factors where gut microbiota could have a significant impact. More and more research is pointing towards the GUT MICROBIOME as the key to health and disease.
There have been many reports of Autism patients undergoing Fecal Microbiota Transplant (FMT). In 2017, there was a high-profile clinical trial published utilizing FMT for patients with autism. In the open-label trial, 18 children with autism underwent two-week antibiotic treatment followed by a bowel cleanse and multiple doses of FMT. The researchers observed an 80% reduction in gastrointestinal symptoms such as altered bowel movements, abdominal pain, and indigestion.
The AMB HMT Dosage
Designed especially for children, this HMT oral drink involves the stool specimens (through stringently screened healthy donors) that go through an isolation and filtration process, which separates the waste particles containing food, hormones etc. and extracts the live bacteria (microbiota) from the specimen.
The extracted microbes from stool samples are thus processed to reduce any odour are then blended with one of a variety of beverages including flavoured milk, soy milk & rice milk under sterile conditions to ensure the highest of quality. This then gives us the HMT product in the liquid oral form. The final product is then stored using the same storage method as our other products, cryogenically at -80°C until it is ready to be used.